Encellin has secured $9.9M in financing to advance its groundbreaking Encapsulated Cell Replacement Therapy (EnCRT) for Type 1 Diabetes (T1D). This funding, led by Khosla Ventures, will propel the Phase 1 clinical trial and support team expansion. Encellin is a 2016 Rosenman Innovator, 2022 RISE Founder, and UCSF alumn, whose technology spun out of UCSF.
From the press release:
SAN FRANCISCO–(BUSINESS WIRE)–Encellin, a biotechnology company developing a cell encapsulation platform with an initial focus on Type 1 Diabetes (T1D), announced the closing of a $9.9M financing round led by Khosla Ventures, with participation from Y Combinator.
The new funding will advance a Phase 1 clinical trial evaluating subcutaneous transplantation of primary islets within Encellin’s EnCRT in T1D. First-in-human data from the Phase 1 study is expected next year. The financing will also be used for team expansion and further development of the technology platform.
“This new financing led by Khosla Ventures, enables us to advance development of our Cell Encapsulation platform, which aims to provide years of therapeutic benefit with a single implant. The technology can be used in a variety of different indications, beginning with chronic endocrine disorders,” said Crystal Nyitray, Ph.D., CEO & Co-Founder, Encellin. “Using advanced nanotechnology and bioengineering, we have developed biocompatible materials into permeable, soft pouches designed to support cell function. We look forward to advancing the use of our EnCRT loaded with primary islet to enable responsive insulin delivery for patients with high risk T1D.”